Huntington’s disease

Origami Therapeutics developing treatments for neurodegenerative diseases with ML and computational chemistry

Beth Hoffman, Origami Therapeutics CEO, talks about how the company’s platform enables the discovery and development of protein degraders and conformation correctors to match the best drug to treat neurodegenerative diseases, such as Huntington’s disease.

SOM’s AI-discovered drug shows promise in Huntington’s disease

A drug originally developed for high blood pressure could find a new use in the treatment of Huntington’s disease, thanks to an artificial intelligence-based drug discovery programme at Spain’s SOM Biotech. SOM3355 (bevantolol hydrochloride) hit its objectives in a phase 2 trial in patients with Huntington’s disease, improving the involuntary, jerky movements known as chorea …

SOM’s AI-discovered drug shows promise in Huntington’s disease Read More »

Ipsen bets on Exicure’s tech as better way to deliver neuro drugs deep into the brain

Ipsen is shoring up its neuroscience pipeline via a deal that gives it the option to license drugs that Exicure is developing for Huntington’s disease and Angelman syndrome. The programs are based on Exicure’s proprietary technology that produces nucleic acid therapies capable of delivery deep into the brain.

Ipsen forges $1bn alliance with Exicure on neurodegenerative diseases

Ipsen’s new chief executive David Loew pledged to ramp up spending on the company’s pipeline when he took the helm last year, and a flurry of licensing deals in the last few weeks shows that push is starting to gather momentum. The French company – which focusing on cancer, neuroscience and rare diseases – has …

Ipsen forges $1bn alliance with Exicure on neurodegenerative diseases Read More »

uniQure Reports Completion of Enrollment in First Cohort of P- I/II Trial for AMT-130 to Treat Huntington’s Disease

Shots: The company has completed the enrollment in the first cohort of P- I/II trial involves assessing AMT-130 in 10 patients, out of which six patients received treatment with AMT-130 and four patients received imitation surgery for early manifest HD The company plans to initiate a second clinical study of AMT-130 in the EU in …

uniQure Reports Completion of Enrollment in First Cohort of P- I/II Trial for AMT-130 to Treat Huntington’s Disease Read More »

Roche stops dosing in trial of Huntington’s disease hopeful tominersen

Roche has stopped dosing in a phase 3 trial of tominersen, a potential Huntington’s disease (HD) drug developed with Ionis, after a pre-planned review by independent experts.  The companies had been working on tominersen since December 2017, when Roche licensed it in from Ionis. There were high expectations for tominersen, which the companies hoped would …

Roche stops dosing in trial of Huntington’s disease hopeful tominersen Read More »

Roche, PicnicHealth start RWD partnership with multiple sclerosis focus

The companies will use a combination of more than seven years of medical record data with five years of prospective data on 5,000 MS patients, including real-world outcomes data and MRI images. Other disease areas to be explored include hematology and rare diseases.